Observational studyBMC oral health2025
Salivary and serum levels of high mobility group box protein 1 in periodontitis: a cross-sectional observational study.
Observational study in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh mobility group box protein 1 (HMGB1) exhibits pro-inflammatory functions in chronic inflammatory diseases and is closely associated with other inflammatory markers contributing to sustained inflammatory milieu. This study aimed to evaluate HMGB1 levels and their associations with tumor necrosis factor alpha (TNFα), transforming growth factor beta (TGFβ) and interleukin- 1b (IL-1β) in the saliva and serum of the periodontitis patients.
methodsSixty-six systematically healthy nonsmoker individuals were enrolled and categorized into three groups: (1) Control, (2) Stage I-II Periodontitis, and (3) Stage III-IV Periodontitis. Comprehensive periodontal assessments were performed. HMGB1, TNFα, IL-1β and TGFβ concentrations were analyzed by enzyme-linked immunosorbent assay (ELISA). One-way ANOVA with Tukey's post-hoc test assessed group differences, and Pearson's correlation evaluated relationships between quantitative variables.
resultsSalivary HMGB1 levels were significantly elevated in both periodontitis groups compared to controls (p < 0.0001). Serum HMGB1 levels were significantly higher in the Stage III-IV periodontitis group than in both the control (p = 0.022) and Stage I-II (p < 0.001) periodontitis groups. Serum HMGB1 showed positive correlations with IL-1β levels in both periodontitis groups (p < 0.05 for Stage I-II; p ≤ 0.01 for Stage III-IV). A significant positive correlation was also observed between salivary HMGB1 and TNFα levels in the Stage I-II periodontitis group (p ≤ 0.01).
conclusionHMGB1 levels increase in saliva and serum as periodontal disease worsens, suggesting enhanced HMGB1 expression was involved in the pathogenetic shifts in the disease process at local and systemic levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.